BRISTOL, Tenn., Feb. 28 (UPI) -- U.S. firm King Pharmaceuticals said Wednesday it has been approved to market its heart drug Altace in a tablet formation.
The drug firm said the Food and Drug Administration has approved its new dug application for the ACE inhibitor drug ramipril in the new dosage form.
The company said it "expects to be in a position to launch the new formulation sometime during the fourth quarter of 2007 or the first quarter of 2008."
Altace is indicated in patients 55 years or older at high risk of developing a major cardiovascular event, either because of a history of coronary artery disease, stroke or peripheral vascular disease, or because of diabetes that is accompanied by at least one other cardiovascular risk factor, such as hypertension or elevated cholesterol.
